Shatavari and PCOS: The Trial Missed Its Main Target, and the Result Is Still Interesting
Shatavari (Asparagus racemosus) has been used in Ayurvedic practice for women's reproductive health for a very long time, which is exactly the kind of pedigree that makes a modern trial both necessary and interesting to read closely. A new randomized, double-blind, placebo-controlled study tested a standardized shatavari root extract in women with Polycystic Ovary Syndrome (PCOS). The coverage says it showed improvement. The trial's own primary outcome says something more complicated.
The results, in order of importance
Researchers in India randomized 70 women aged 20 to 40 with PCOS to either standardized shatavari root extract or placebo for twelve weeks, with 66 completing the full protocol [1]. Neither the participants nor the investigators knew who was getting what. Assessments happened at baseline, week 4, week 8, and week 12, with bloodwork at the start and end covering HbA1c, lipids, insulin, reproductive hormones, and liver, kidney, and thyroid function.
The primary outcome was change in ovarian and endometrial measures. Ovarian volume did not differ between the groups (p = 0.254). That is the trial's main question, and the answer was no.
Three secondary findings did move. Perceived stress dropped substantially in the shatavari group, by 6.64 points on the PSS-10 scale, with a p-value below 0.0001. Antral follicle count decreased. Endometrial thickness increased modestly. Safety looked reassuring: no serious adverse events, and mild-to-moderate events in 11.4 percent of the shatavari group against 8.5 percent on placebo.
What didn't move deserves equal billing. No significant change in BMI. No significant change in hormone levels. No significant change in HbA1c, insulin, or lipids.
What the headline leaves out
PCOS is characterized in large part by androgen excess and insulin resistance. A twelve-week trial reporting no change in reproductive hormones and no change in insulin or HbA1c has not demonstrated an effect on the mechanisms that define the condition. Calling that "improvement in PCOS" stretches further than the data reaches.
The stress finding is the most robust number in the paper and also the one most vulnerable to bias. The PSS-10 is a self-report questionnaire, and a 6.64-point shift is large for a twelve-week herbal intervention. Blinding helps, though it isn't airtight once a participant notices they feel different. Seventy participants is also a small sample for drawing firm conclusions about anything.
Set beside other options, the picture sharpens. A 2026 network meta-analysis compared GLP-1 receptor agonists, metformin, and myo-inositol across sixteen randomized trials [2]. The combination of a GLP-1 agonist plus metformin produced the largest weight and BMI reductions. None of those interventions significantly improved insulin resistance as measured by HOMA-IR, which tells you how stubborn that particular target is even with pharmaceutical tools. A separate meta-analysis of twelve trials found cinnamon supplementation improved fasting glucose, insulin resistance, and cholesterol in women with PCOS [3]. So other botanicals in this space have produced metabolic signals that shatavari did not.
The naturopathic lens
PCOS is not one condition wearing one face. Clinically it sorts roughly into an insulin-resistant presentation, an adrenal or stress-driven presentation, and an inflammatory presentation, with plenty of overlap. Two women can meet the same diagnostic criteria and need almost nothing in common.
Read through that lens, a botanical that lowers perceived stress without touching insulin isn't a failure. It is a poorly matched intervention for one phenotype and a plausibly reasonable one for another. The women in this trial weren't sorted by presentation, so a true benefit in a stress-driven subgroup could easily be diluted into nonsignificance across a mixed sample. That's a study design question, not a verdict on the herb.
I would also resist writing off the stress result because it's subjective. The hypothalamic-pituitary-adrenal axis participates in PCOS, and chronic stress load affects cycles, sleep, appetite, and insulin signaling over time. Beyond mechanism, women with PCOS carry a documented burden of anxiety and distress that goes chronically under-addressed while the conversation stays on labs. An intervention that helps someone feel less overwhelmed is doing something useful even if it never shows up on a metabolic panel.
How I'd think about this
Treat this as an early, small, and mostly negative trial with one interesting positive signal, seeing as that's what it is. It doesn't establish shatavari as a PCOS treatment, and the endometrial thickness change should not be read as a fertility outcome. It wasn't studied as one.
If you have PCOS and are curious about botanicals, the more productive question is which version of PCOS you have. Fasting insulin, HbA1c, androgens, and a frank look at your stress and sleep load will tell you more about where to aim than any single herb's press coverage will. Bring shatavari to your provider rather than adding it on your own, since herbs carry real pharmacology and can interact with hormonal medications.
References
Mhatre Y, Jadhav P, Malik A, Srivathsan M, Langade D. Efficacy and safety of Shatavari root extract in women with Polycystic Ovarian Syndrome: a randomized, double-blind, placebo-controlled trial. Front Endocrinol (Lausanne). 2026;17:1769773. PMID 41816216. DOI 10.3389/fendo.2026.1769773. Trial registration CTRI/2024/10/074660.
Omarion A, Ayasa Y, Omarion Z, Jayouse B, Ayesh H. Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis. Front Endocrinol (Lausanne). 2026;17:1833904. PMID 42490840. DOI 10.3389/fendo.2026.1833904. (A published correction to this article appeared as PMID 42549142.)
Xiaomei Z, Xiaoyan F. Effect of cinnamon as a Chinese herbal medicine on markers of cardiovascular risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2024;300:253–261. PMID 39053085. DOI 10.1016/j.ejogrb.2024.07.032
American Botanical Council. Shatavari shows improvement in polycystic ovary syndrome. HerbClip, HerbalGram issue 788, 2026. https://www.herbalgram.org/resources/herbclip/issues/2026/issue-788/shatavari-polycystic-ovary-syndrome/ (secondary review of the primary trial above).
Reference metadata verified against PubMed.
A closing note
This is educational information and not medical advice, and it can't substitute for care from a clinician who knows your history and your labs. PCOS is a real endocrine condition that deserves proper evaluation. If you're managing it, or trying to conceive, or taking hormonal medication of any kind, please talk with your own provider before adding a botanical.
If this resonates with what you're experiencing and you'd like to explore a naturopathic approach, book a consultation with our clinic.
Comments